Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127378531 | 12737853 | 1 | I | 20160908 | 20160913 | 20160913 | EXP | NL-PFIZER INC-2016425452 | PFIZER | KOLWIJCK, E.. VORICONAZOLE-SUSCEPTIBLE AND VORICONAZOLE-RESISTANT ASPERGILLUS FUMIGATUS COINFECTION. AMERICAN JOURNAL OF RESPIRATORY + CRITICAL CARE MEDICINE. 2016;193(8):927-929 | 71.00 | YR | M | Y | 0.00000 | 20160913 | MD | NL | NL |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127378531 | 12737853 | 1 | PS | VORICONAZOLE. | VORICONAZOLE | 1 | UNK | 21266 | |||||||||||
127378531 | 12737853 | 2 | C | ANIDULAFUNGIN | ANIDULAFUNGIN | 1 | UNK | 0 | |||||||||||
127378531 | 12737853 | 3 | C | MEROPENEM. | MEROPENEM | 1 | UNK | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127378531 | 12737853 | 1 | Aspergillus infection |
127378531 | 12737853 | 2 | Aspergillus infection |
127378531 | 12737853 | 3 | Aspergillus infection |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127378531 | 12737853 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127378531 | 12737853 | Drug ineffective | |
127378531 | 12737853 | Pathogen resistance |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |